Ludwig Enterprises Announces Two Abstracts Accepted for Publication in the Journal of Clinical Oncology
Ludwig Enterprises has achieved a significant milestone with two abstracts accepted for publication in the prestigious Journal of Clinical Oncology. The abstracts focus on their innovative mRNA cancer screening program, specifically addressing breast cancer detection through non-invasive methods.
The accepted abstracts are titled "Non-invasively Collected Buccal Cell mRNA Reveals Novel Breast Cancer Signal" and "A Novel Machine Learning Approach to Breast Cancer Screening Using Non-invasive mRNA Collection." The company's scientific team, led by CSO Marvin S. Hausman MD, will present at the ASCO 2025 Annual Meeting in Chicago from May 30th to June 3rd.
This presentation opportunity at ASCO will allow Ludwig to showcase their proprietary cancer diagnostic technology to major laboratory, telehealth, and pharmaceutical companies. The company plans to highlight their upcoming launch of a noninvasive cheek cell breast cancer test, positioning it as a potential game-changing development in cancer diagnostics.
Ludwig Enterprises ha raggiunto un traguardo importante con l'accettazione di due abstract per la pubblicazione sul prestigioso Journal of Clinical Oncology. Gli abstract riguardano il loro innovativo programma di screening del cancro basato su mRNA, focalizzandosi in particolare sulla rilevazione del cancro al seno tramite metodi non invasivi.
Gli abstract accettati si intitolano "Non-invasively Collected Buccal Cell mRNA Reveals Novel Breast Cancer Signal" e "A Novel Machine Learning Approach to Breast Cancer Screening Using Non-invasive mRNA Collection." Il team scientifico dell'azienda, guidato dal CSO Marvin S. Hausman MD, presenterà al ASCO 2025 Annual Meeting a Chicago dal 30 maggio al 3 giugno.
Questa opportunità di presentazione all'ASCO permetterà a Ludwig di mostrare la loro tecnologia proprietaria per la diagnosi del cancro ai principali laboratori, aziende di telemedicina e case farmaceutiche. L'azienda intende mettere in evidenza il prossimo lancio di un test non invasivo per il cancro al seno basato sulle cellule della guancia, posizionandolo come una possibile svolta nel campo della diagnostica oncologica.
Ludwig Enterprises ha alcanzado un hito importante con la aceptación de dos resúmenes para publicación en la prestigiosa Journal of Clinical Oncology. Los resúmenes se centran en su innovador programa de detección de cáncer basado en mRNA, específicamente en la detección del cáncer de mama mediante métodos no invasivos.
Los resúmenes aceptados se titulan "Non-invasively Collected Buccal Cell mRNA Reveals Novel Breast Cancer Signal" y "A Novel Machine Learning Approach to Breast Cancer Screening Using Non-invasive mRNA Collection." El equipo científico de la compañía, liderado por el CSO Marvin S. Hausman MD, presentará en la Reunión Anual ASCO 2025 en Chicago del 30 de mayo al 3 de junio.
Esta oportunidad de presentación en ASCO permitirá a Ludwig mostrar su tecnología patentada para el diagnóstico del cáncer a importantes laboratorios, empresas de telemedicina y farmacéuticas. La compañía planea destacar el próximo lanzamiento de una prueba no invasiva para el cáncer de mama basada en células de la mejilla, posicionándola como un posible avance revolucionario en el diagnóstico del cáncer.
Ludwig Enterprises가 권위 있는 Journal of Clinical Oncology에 두 개의 초록이 게재 승인되는 중요한 성과를 달성했습니다. 이 초록들은 혁신적인 mRNA 암 검사 프로그램에 초점을 맞추고 있으며, 특히 비침습적 방법을 통한 유방암 검출을 다루고 있습니다.
승인된 초록 제목은 "Non-invasively Collected Buccal Cell mRNA Reveals Novel Breast Cancer Signal"와 "A Novel Machine Learning Approach to Breast Cancer Screening Using Non-invasive mRNA Collection"입니다. 회사의 과학 팀은 CSO Marvin S. Hausman MD의 지도 하에 5월 30일부터 6월 3일까지 시카고에서 열리는 ASCO 2025 연례 회의에서 발표할 예정입니다.
ASCO에서의 이번 발표 기회를 통해 Ludwig는 주요 실험실, 원격 의료 및 제약 회사들에게 자사의 독점 암 진단 기술을 선보일 수 있습니다. 회사는 비침습적인 볼 점막 세포 기반 유방암 검사 출시를 앞두고 있으며, 이를 암 진단 분야의 획기적인 발전으로 자리매김할 계획입니다.
Ludwig Enterprises a atteint une étape importante avec l'acceptation de deux résumés pour publication dans le prestigieux Journal of Clinical Oncology. Ces résumés portent sur leur programme innovant de dépistage du cancer par ARN messager (mRNA), ciblant spécifiquement la détection du cancer du sein par des méthodes non invasives.
Les résumés acceptés s'intitulent "Non-invasively Collected Buccal Cell mRNA Reveals Novel Breast Cancer Signal" et "A Novel Machine Learning Approach to Breast Cancer Screening Using Non-invasive mRNA Collection." L'équipe scientifique de l'entreprise, dirigée par le CSO Marvin S. Hausman MD, présentera lors du ASCO 2025 Annual Meeting à Chicago du 30 mai au 3 juin.
Cette opportunité de présentation à l'ASCO permettra à Ludwig de mettre en avant leur technologie propriétaire de diagnostic du cancer auprès des principaux laboratoires, entreprises de télésanté et sociétés pharmaceutiques. L'entreprise prévoit de souligner le lancement prochain d'un test non invasif du cancer du sein basé sur les cellules de la joue, qu'elle présente comme une avancée potentiellement révolutionnaire dans le domaine du diagnostic oncologique.
Ludwig Enterprises hat einen bedeutenden Meilenstein erreicht: Zwei Abstracts wurden zur Veröffentlichung im renommierten Journal of Clinical Oncology akzeptiert. Die Abstracts befassen sich mit ihrem innovativen mRNA-Krebs-Screening-Programm, das sich speziell auf die nicht-invasive Erkennung von Brustkrebs konzentriert.
Die akzeptierten Abstracts tragen die Titel "Non-invasively Collected Buccal Cell mRNA Reveals Novel Breast Cancer Signal" und "A Novel Machine Learning Approach to Breast Cancer Screening Using Non-invasive mRNA Collection." Das wissenschaftliche Team des Unternehmens unter der Leitung von CSO Marvin S. Hausman MD wird auf dem ASCO 2025 Annual Meeting in Chicago vom 30. Mai bis 3. Juni präsentieren.
Diese Präsentationsmöglichkeit bei ASCO ermöglicht es Ludwig, seine firmeneigene Krebsdiagnosetechnologie großen Laboren, Telemedizin- und Pharmaunternehmen vorzustellen. Das Unternehmen plant, die bevorstehende Einführung eines nicht-invasiven Wangenzelltests zur Brustkrebserkennung hervorzuheben und sieht darin eine potenzielle bahnbrechende Entwicklung in der Krebsdiagnostik.
- Two abstracts accepted for publication in prestigious Journal of Clinical Oncology
- Development of proprietary mRNA cancer screening program
- Novel non-invasive breast cancer diagnostic test approaching launch phase
- Potential business development opportunities through ASCO meeting with pharma companies and laboratories
- None.
Marvin S. Hausman MD to discuss screening program at ASCO
MIAMI, FLORIDA / ACCESS Newswire / April 29, 2025 / Ludwig Enterprises, Inc. (the "Company") today announced the acceptance for publication in the Journal of Clinical Oncology two abstracts related to its mRNA cancer program. These abstracts are titled: "Non-invasively Collected Buccal Cell mRNA Reveals Novel Breast Cancer Signal," and "A Novel Machine Learning Approach to Breast Cancer Screening Using Non-invasive mRNA Collection."
Marvin S. Hausman MD, CSO of the Company, stated: "The ASCO 2025 Annual Meeting is a great opportunity to discuss and show our proprietary mRNA cancer screening program to major laboratory, telehealth and pharmaceutical companies. This meeting brings together in a single venue an array of pharmaceutical analysts and major pharma companies who are focused on cancer and is a unique opportunity to promote what I believe is our game-changing cancer diagnostic program."
Members of our scientific and marketing team plan to be in attendance at the upcoming 2025 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, May 30th to June 3rd. The Annual Meeting provides a timely opportunity to engage with clinical trial investigators, laboratory experts and major pharmaceutical companies and share information on our cancer diagnostic program, especially the upcoming launch of our noninvasive cheek cell breast cancer test.
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (which is in the process of changing its name to Revealia Diagnostics, Inc.), a biotech and healthcare holding company, is a global - innovator in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor, and create solutions to mitigate chronic inflammation, the causative agent of illnesses such as cancer and heart disease, which are responsible for more than
For more information, please visit: http://www.ludwigent.com.
About Revealia Diagnostics™
Revealia™ is a breast cancer screening test that utilizes a proprietary mRNA microarray to establish a personalized inflammatory index that provides a patient with reliable information that can assist in their healthcare medical decisions. - Artificial intelligence (AI) is used to determine a risk score, which is derived from a specific array of inflammatory biomarkers and comparing it to a database of previously analyzed patients.
For more information, please visit: www.revealia.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
FOR FURTHER INFORMATION:
CONTACT:
Ludwig Enterprises, Inc.
www.ludwigent.com
Twitter: @LUDG_inc
Charles Todd, Jr. - HQ@ludwigent.com
SOURCE: Ludwig Enterprises, Inc.
View the original press release on ACCESS Newswire
FAQ
What are the two abstracts from Ludwig Enterprises (LUDG) accepted by Journal of Clinical Oncology in 2025?
When and where will LUDG present its mRNA cancer screening program at ASCO 2025?
What is LUDG's new breast cancer testing method?
Who will Ludwig Enterprises (LUDG) target at the ASCO 2025 meeting?
What makes LUDG's cancer screening program innovative?
